OIP5 and cancer: The difference in expression levels of OIP5-AS1 observed in our study may be attributed to the distinct 5-FU mechanisms of action compared to oxaliplatin, cisplatin, or other anti-cancer drugs, as well as cell-specific responses to a distinct dose of 5-FU in generating drug resistance sub-cell line, and experimental conditions.